Vistagen Therapeutics (VTGN) R&D In Process (2020 - 2021)
Vistagen Therapeutics' R&D In Process history spans 4 years, with the latest figure at $5.6 million for Q2 2021.
- For Q2 2021, R&D In Process rose 223.68% year-over-year to $5.6 million; the TTM value through Jun 2021 reached $22.4 million, down 7.9%, while the annual FY2013 figure was $7.5 million, 0.0% changed from the prior year.
- R&D In Process for Q2 2021 was $5.6 million at Vistagen Therapeutics, up from $1.7 million in the prior quarter.
- Across five years, R&D In Process topped out at $5.6 million in Q2 2021 and bottomed at $1.7 million in Q2 2020.